BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Samuel P, Pink RC, Brooks SA, Carter DR. miRNAs and ovarian cancer: a miRiad of mechanisms to induce cisplatin drug resistance. Expert Rev Anticancer Ther. 2016;16:57-70. [PMID: 26567444 DOI: 10.1586/14737140.2016.1121107] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
Number Citing Articles
1 Carollo E, Paris B, Samuel P, Pantazi P, Bartelli TF, Dias-Neto E, Brooks SA, Pink RC, Carter DRF. Detecting ovarian cancer using extracellular vesicles: progress and possibilities. Biochem Soc Trans 2019;47:295-304. [PMID: 30700499 DOI: 10.1042/BST20180286] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 3.7] [Reference Citation Analysis]
2 Zhang XY, Li YF, Ma H, Gao YH. Regulation of MYB mediated cisplatin resistance of ovarian cancer cells involves miR-21-wnt signaling axis. Sci Rep 2020;10:6893. [PMID: 32327705 DOI: 10.1038/s41598-020-63396-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
3 Guo C, Song C, Zhang J, Gao Y, Qi Y, Zhao Z, Yuan C. Revisiting chemoresistance in ovarian cancer: Mechanism, biomarkers, and precision medicine. Genes & Diseases 2020. [DOI: 10.1016/j.gendis.2020.11.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Wu G, Yan Y, Zhou Y, Duan Y, Zeng S, Wang X, Lin W, Ou C, Zhou J, Xu Z. Sulforaphane: Expected to Become a Novel Antitumor Compound. Oncol Res 2020;28:439-46. [PMID: 32111265 DOI: 10.3727/096504020X15828892654385] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 7.5] [Reference Citation Analysis]
5 Wu D, Lu P, Mi X, Miao J. Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85. Arch Gynecol Obstet 2018;297:699-707. [DOI: 10.1007/s00404-018-4649-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
6 Samuel P, Fabbri M, Carter DRF. Mechanisms of Drug Resistance in Cancer: The Role of Extracellular Vesicles. Proteomics 2017;17. [PMID: 28941129 DOI: 10.1002/pmic.201600375] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 7.2] [Reference Citation Analysis]
7 Yao J, Dai Q, Liu Z, Zhou L, Xu J. Circular RNAs in Organ Fibrosis. In: Xiao J, editor. Circular RNAs. Singapore: Springer; 2018. pp. 259-73. [DOI: 10.1007/978-981-13-1426-1_21] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
8 Zhao Y, Xia H. Oridonin elevates sensitivity of ovarian carcinoma cells to cisplatin via suppressing cisplatin-mediated autophagy. Life Sciences 2019;233:116709. [DOI: 10.1016/j.lfs.2019.116709] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
9 Chen Y, Wang L, Zhou J. Effects of microRNA‐1271 on ovarian cancer via inhibition of epithelial‐mesenchymal transition and cisplatin resistance. J Obstet Gynaecol Res 2019;45:2243-54. [DOI: 10.1111/jog.14079] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
10 Xiao S, Li Y, Pan Q, Ye M, He S, Tian Q, Xue M. MiR-34c/SOX9 axis regulates the chemoresistance of ovarian cancer cell to cisplatin-based chemotherapy. J Cell Biochem 2019;120:2940-53. [PMID: 30537410 DOI: 10.1002/jcb.26865] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
11 Prahm KP, Høgdall C, Karlsen MA, Christensen IJ, Novotny GW, Høgdall E. Identification and validation of potential prognostic and predictive miRNAs of epithelial ovarian cancer. PLoS One 2018;13:e0207319. [PMID: 30475821 DOI: 10.1371/journal.pone.0207319] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
12 Guo J, Pan H. Long Noncoding RNA LINC01125 Enhances Cisplatin Sensitivity of Ovarian Cancer via miR-1972. Med Sci Monit 2019;25:9844-54. [PMID: 31865363 DOI: 10.12659/MSM.916820] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
13 Marí-Alexandre J, Carcelén AP, Agababyan C, Moreno-Manuel A, García-Oms J, Calabuig-Fariñas S, Gilabert-Estellés J. Interplay Between MicroRNAs and Oxidative Stress in Ovarian Conditions with a Focus on Ovarian Cancer and Endometriosis. Int J Mol Sci 2019;20:E5322. [PMID: 31731537 DOI: 10.3390/ijms20215322] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
14 Samuel P, Mulcahy LA, Furlong F, McCarthy HO, Brooks SA, Fabbri M, Pink RC, Carter DRF. Cisplatin induces the release of extracellular vesicles from ovarian cancer cells that can induce invasiveness and drug resistance in bystander cells. Philos Trans R Soc Lond B Biol Sci 2018;373:20170065. [PMID: 29158318 DOI: 10.1098/rstb.2017.0065] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 12.0] [Reference Citation Analysis]
15 Liu S, Li L, Li M, Zhang J. Effect of miR-26b-5p on cis-diamine dichloroplatinum-induced ovarian granulosa cell injury by targeting MAP3K9. In Vitro Cell Dev Biol Anim 2020;56:213-21. [PMID: 32185607 DOI: 10.1007/s11626-020-00439-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Khan MA, Vikramdeo KS, Sudan SK, Singh S, Wilhite A, Dasgupta S, Rocconi RP, Singh AP. Platinum-resistant ovarian cancer: From drug resistance mechanisms to liquid biopsy-based biomarkers for disease management. Semin Cancer Biol 2021:S1044-579X(21)00217-0. [PMID: 34418576 DOI: 10.1016/j.semcancer.2021.08.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Bieg D, Sypniewski D, Nowak E, Bednarek I. Morin decreases galectin-3 expression and sensitizes ovarian cancer cells to cisplatin. Arch Gynecol Obstet 2018;298:1181-94. [PMID: 30267152 DOI: 10.1007/s00404-018-4912-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
18 Sun Y, Shi T, Zhou Y, Zhou L, Sun B. Folate-decorated and NIR-triggered nanoparticles loaded with platinum(IV)-prodrug plus 5-fluorouracil for targeted and chemo-photothermal combination therapy. Journal of Drug Delivery Science and Technology 2018;48:40-8. [DOI: 10.1016/j.jddst.2018.08.021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
19 Shafaee MMA, Mohamed HS, Ahmed SA, Kandeil MA; Chemistry department, Faculty of Science, Beni-Suef University, Egypt, Research Institute of Medicinal and Aromatic Plants, Beni-Suef University, Egypt;, Chemistry department, Faculty of Science, Beni-Suef University, Egypt;, Biochemistry department, Faculty of Veterinary medicine, Beni-Suef University, Egypt;. Effect of selenium and nano-selenium on cisplatin-induced nephrotoxicity in albino rats. Ukr Biochem J 2019;91:86-95. [DOI: 10.15407/ubj91.06.086] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
20 Xu M, Liu X, Li P, Yang Y, Zhang W, Zhao S, Zeng Y, Zhou X, Zeng LH, Yang G. Modified Natriuretic Peptides and their Potential Role in Cancer Treatment. Biomed J 2021:S2319-4170(21)00085-8. [PMID: 34237455 DOI: 10.1016/j.bj.2021.06.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
21 Yin F, Zhang Q, Dong Z, Hu J, Ma Z. LncRNA HOTTIP Participates in Cisplatin Resistance of Tumor Cells by Regulating miR-137 Expression in Pancreatic Cancer. Onco Targets Ther 2020;13:2689-99. [PMID: 32280243 DOI: 10.2147/OTT.S234924] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
22 Zhang Y, Huang S, Guo Y, Li L. MiR-1294 confers cisplatin resistance in ovarian Cancer cells by targeting IGF1R. Biomed Pharmacother 2018;106:1357-63. [PMID: 30119207 DOI: 10.1016/j.biopha.2018.07.059] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
23 Liu R, Zhang Y, Sun P, Wang C. DDP-resistant ovarian cancer cells-derived exosomal microRNA-30a-5p reduces the resistance of ovarian cancer cells to DDP. Open Biol 2020;10:190173. [PMID: 32343928 DOI: 10.1098/rsob.190173] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
24 Han X, Zhen S, Ye Z, Lu J, Wang L, Li P, Li J, Zheng X, Li H, Chen W, Li X, Zhao L. A Feedback Loop Between miR-30a/c-5p and DNMT1 Mediates Cisplatin Resistance in Ovarian Cancer Cells. Cell Physiol Biochem. 2017;41:973-986. [PMID: 28222434 DOI: 10.1159/000460618] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 7.6] [Reference Citation Analysis]
25 Samuel P, Carter DR. The Diagnostic and Prognostic Potential of microRNAs in Epithelial Ovarian Carcinoma. Mol Diagn Ther 2017;21:59-73. [PMID: 27718164 DOI: 10.1007/s40291-016-0242-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
26 Zou X, Zhao Y, Liang X, Wang H, Zhu Y, Shao Q. Double Insurance for OC: miRNA-Mediated Platinum Resistance and Immune Escape. Front Immunol 2021;12:641937. [PMID: 33868274 DOI: 10.3389/fimmu.2021.641937] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Hao G, Ding Y, Wen H, Li X, Zhang W, Su H, Liu D, Xie N. Attenuation of deregulated miR-369-3p expression sensitizes non-small cell lung cancer cells to cisplatin via modulation of the nucleotide sugar transporter SLC35F5. Biochemical and Biophysical Research Communications 2017;488:501-8. [DOI: 10.1016/j.bbrc.2017.05.075] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
28 Maiuolo J, Musolino V, Gliozzi M, Carresi C, Oppedisano F, Nucera S, Scarano F, Scicchitano M, Guarnieri L, Bosco F, Macrì R, Ruga S, Cardamone A, Coppoletta AR, Ilari S, Mollace A, Muscoli C, Cognetti F, Mollace V. The Employment of Genera Vaccinium, Citrus, Olea, and Cynara Polyphenols for the Reduction of Selected Anti-Cancer Drug Side Effects. Nutrients 2022;14:1574. [DOI: 10.3390/nu14081574] [Reference Citation Analysis]
29 Fabbri M. MicroRNAs and miRceptors: a new mechanism of action for intercellular communication. Philos Trans R Soc Lond B Biol Sci 2018;373:20160486. [PMID: 29158315 DOI: 10.1098/rstb.2016.0486] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
30 Liang J, Tian XF, Yang W. Effects of long non-coding RNA Opa-interacting protein 5 antisense RNA 1 on colon cancer cell resistance to oxaliplatin and its regulation of microRNA-137. World J Gastroenterol 2020; 26(13): 1474-1489 [PMID: 32308348 DOI: 10.3748/wjg.v26.i13.1474] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
31 Niu YC, Tong J, Shi XF, Zhang T. MicroRNA-654-3p enhances cisplatin sensitivity by targeting QPRT and inhibiting the PI3K/AKT signaling pathway in ovarian cancer cells. Exp Ther Med 2020;20:1467-79. [PMID: 32742380 DOI: 10.3892/etm.2020.8878] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
32 Zhu K, Zhu J, Geng J, Zhang Y, Qin Y, Wang F, Weng Y. circSNX6 (hsa_circ_0031608) enhances drug resistance of non-small cell lung cancer (NSCLC) via miR-137. Biochem Biophys Res Commun 2021;567:79-85. [PMID: 34144504 DOI: 10.1016/j.bbrc.2021.06.032] [Reference Citation Analysis]